Skip to main content
Premium Trial:

Request an Annual Quote

BG Medicine Raises $12.8M in Public Offering of Stock

NEW YORK (GenomeWeb News) – BG Medicine has completed a public offering of 6 million shares of its common stock, raising net proceeds of around $12.8 million.

The Waltham, Mass.-based cardiovascular diagnostics firm said that the underwriters of the offering also exercised their option to purchase 900,000 additional shares. The offering, which was priced at $2 per share, was launched last week.

Proceeds from the offering will go toward operations, including advancing commercialization of BGM's tests in the US and Europe, as well as general corporate purposes, the firm said.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.